| KaloBios Pharmaceuticals, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120020986 | Antibodies to the PcrV Antigen of Pseudomonas aeruginosa - The current invention provides high-affinity antibodies to the | 01-26-2012 |
| 20120009191 | METHODS OF TREATING BONE-LOSS DISORDERS USING A GM-CSF ANTAGONIST - The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of bone loss disorders, such as osteopenia. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, to a patient that has a bone loss disorder and pharmaceutical compositions comprising such antagonists. | 01-12-2012 |
| 20110245100 | GENERATION OF ANTIBODIES TO AN EPITOPE OF INTEREST - The invention provides methods of obtaining antibodies to an epitope of interest based on an anti-hapten focused library. | 10-06-2011 |
| 20110243934 | EPHA3 ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA - The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of multiple myeloma. | 10-06-2011 |
| 20110165172 | METHOD OF TREATING A STAPHYLOCOCCUS INFECTION IN A PATIENT HAVING A LOW-LEVEL PATHOGENIC PSEUDOMONAS AERUGINOSA INFECTION - This invention provides methods of treating patients having a | 07-07-2011 |
| 20110123549 | Antibodies to EphA3 - The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies. | 05-26-2011 |
| 20100272736 | COMBINATION ANTIBIOTIC AND ANTIBODY THERAPY FOR THE TREATMENT OF PSEUDOMONAS AERUGINOSA INFECTION - The present invention provides improved pharmaceutical compositions and methods of treating or preventing development of bacteremia associated with | 10-28-2010 |
| 20100226930 | Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3 - The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders. | 09-09-2010 |
| 20100215650 | METHODS OF TREATING DEMENTIA USING A GM-CSF ANTAGONIST - The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists. | 08-26-2010 |
| 20090274706 | ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR - The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies. | 11-05-2009 |
| 20090263387 | Neutralization of GM-CSF for the Treatment of Heart Failure - This invention relates to methods of treating a patient suffering from heart failure, or a patient at risk for heart failure, using a GM-CSF antagonist. | 10-22-2009 |
| 20090191186 | Antibodies to the PcrV Antigen of Pseudomonas aeruginosa - The current invention provides high-affinity antibodies to the | 07-30-2009 |
| 20080286272 | EphA3 Antibodies for the Treatment of Solid Tumors - The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors. | 11-20-2008 |
| 20080206241 | Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist - The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of chronic inflammatory disease, such as rheumatoid arthritis. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, and an anti-folate compounds, e.g., methotrexate, to a patient that has RA and pharmaceutical compositions comprising such antagonists. | 08-28-2008 |
